Ms. Bui brings more than 15 years of equity research, communications and investor relations experience to Halozyme. She joined Halozyme in 2022 following the acquisition of Antares Pharma, Inc. where she served as the Vice President of Investor Relations and Corporate Communications leading a strategic investor relations program that effectively articulated the company’s growth initiatives, commercial and clinical developments, and operational and financial performance with the investment community.
Prior to Halozyme, Ms. Bui served as Senior Vice President, Investor Relations at The Ruth Group, a boutique investor relations firm specializing in the life science and medical technology industries. In her role, she primarily advised public and private healthcare companies and acted as a senior advisor to executive management teams on strategic communications, financial reporting, crisis communications and capital raises. Previously, she served as a Director at KCSA Strategic Communications, a public and investor relations agency. She started her professional career as a buy-side healthcare analyst for a small cap fund at Lazard Asset Management and an institutional equity sales associate at CJS Securities.
Ms. Bui received her B.S. in Marketing from the University of New Orleans.